LABP Projected Dividend Yield

Landos Biopharma Inc ( NASDAQ : LABP )

Landos Biopharma is a clinical-stage biopharmaceutical company focused on the development of oral therapeutics for patients with certain immunology diseases. Co.'s main candidate is NX-13, an oral, gut-selective NLRX1 agonist. In addition to NX-13, Co. has several preclinical product candidates: LABP-73, an oral, small molecule NLRX1 pathway agonist for the treatment of asthma and Chronic Obstructive Pulmonary Disease; LABP-66, an oral, small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis, and Alzheimer's disease; and LABP-69, an oral, small molecule PLXDC2 pathway agonist in development for the treatment of diabetic nephropathy and rheumatoid arthritis.

20 YEAR PERFORMANCE RESULTS